Stockhead’s Ashtyn Hiron sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news.
AdAlta announced a partnership with venture capital firm SYNthesis BioVentures Fund (SYNBV), the companies have paired up to create a new jointly owned company.
Once established, the company will create a pathway to western regulated markets for Asian innovation in the field of cellular immunotherapies.
Tune in to hear AdAlta’s Tim Oldham on the company’s new partnership, AD214 and and what’s next for the company.
The post Long Shortz with AdAlta: Strengthening bonds in the fight against cancer appeared first on Stockhead.
